Attached files

file filename
10-Q - 10-Q - Talecris Biotherapeutics Holdings Corp.a10-17610_110q.htm
EX-31.2 - EX-31.2 - Talecris Biotherapeutics Holdings Corp.a10-17610_1ex31d2.htm
EX-31.1 - EX-31.1 - Talecris Biotherapeutics Holdings Corp.a10-17610_1ex31d1.htm
EX-32.1 - EX-32.1 - Talecris Biotherapeutics Holdings Corp.a10-17610_1ex32d1.htm

Exhibit 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Talecris Biotherapeutics Holdings Corp. (the “Company”) for the quarter ended September 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Dated: October 28, 2010

 

 

 

/S/ John M. Hanson

 

John M. Hanson

 

Executive Vice President and Chief Financial Officer